Conference Coverage

Complete Conference Coverage

Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer

Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer

CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.

Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy

Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy

Researchers find that surgical decision making is often driven by factors beyond extent of disease.

Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment

Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment

Among breast cancer patients on adjuvant trastuzumab, lisinopril and carvedilol reduced cardiotoxicity, but only for those in the anthracycline cohort.

Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer

Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer

The immune marker PD1 may be prognostic for survival in patients with TNBC who achieve a pathologic complete response after neoadjuvant therapy.

Rates of Adverse Events Similar Regardless of IMRT Boost Type

Rates of Adverse Events Similar Regardless of IMRT Boost Type

The rates of adverse events seen across dose schedule type for patients who underwent IMRT were roughly similar.

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.

TAILORx Shows Black Women With Breast Cancer Have Worse Clinical Outcomes

TAILORx Shows Black Women With Breast Cancer Have Worse Clinical Outcomes

Black women with the most common type of breast cancer had worse clinical outcomes compared with white women, despite receiving similar systemic therapy.

Partial-Breast Irradiation Not Equal to Whole-Breast Irradiation in Early-Stage Breast Cancer

Partial-Breast Irradiation Not Equal to Whole-Breast Irradiation in Early-Stage Breast Cancer

Partial-breast irradiation failed to meet protocol-defined measures for equivalence.

Alpelisib Plus Fulvestrant Continues to Show Improved PFS in PIK3CA-Mutant, HR+, HER2- Advanced Breast Cancer

Alpelisib Plus Fulvestrant Continues to Show Improved PFS in PIK3CA-Mutant, HR+, HER2- Advanced Breast Cancer

Alpelisib plus fulvestrant consistently resulted in prolonged PFS among patients with HR-positive, HER2-negative advanced breast cancer who also had PIK3CA mutations.

High CTC Count Favors Chemotherapy in First-Line ER+, HER2- Metastatic Breast Cancer

High CTC Count Favors Chemotherapy in First-Line ER+, HER2- Metastatic Breast Cancer

CTC count may help guide the decision between first-line chemotherapy or endocrine therapy in ER-positive, HER-negative metastatic breast cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs